

Mexico Pulmonary Arterial Hypertension Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, End User, and Region, 2026-2034

<https://marketpublishers.com/r/M2BE9FAAE269EN.html>

Date: June 2026

Pages: 117

Price: US\$ 3,999.00 (Single User License)

ID: M2BE9FAAE269EN

Abstracts

The Mexico pulmonary arterial hypertension drugs market size reached USD 100.9 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 159.3 Million by 2034 , exhibiting a growth rate (CAGR) of 4.94% during 2026-2034 . The rising disease awareness, increasing government healthcare spending, growing access to advanced therapies, and the expanding availability of generic formulations, making treatment more affordable and accessible for a broader patient population, are some of the key factors contributing to the market growth.

MEXICO PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET TRENDS:

Increasing Adoption of Combination Therapy for PAH Treatment

Combination therapy, where two or more drugs are used together, is becoming a key trend in the treatment of pulmonary arterial hypertension (PAH) in Mexico. This approach targets multiple disease pathways like endothelin, nitric oxide, and prostacyclin, improving patient outcomes and reducing hospitalization rates. The share of diagnosed PAH patients in Mexico treated with dual or triple therapy regimens is therefore expected to rise, driven by greater clinical adoption and promising outcomes from international studies. Pharmaceutical companies are increasingly promoting combination treatments, such as endothelin receptor antagonists (ERAs) like bosentan and phosphodiesterase-5 inhibitors (PDE5i) like sildenafil. The availability of fixed-dose combinations (FDCs) has further enhanced patient adherence by reducing the pill burden and simplifying dosing. This shift is particularly crucial in Mexico, where early

diagnosis and aggressive treatment are essential due to late-stage patient referrals. Studies suggest that combination therapy can reduce clinical worsening compared to monotherapy, thus creating a positive outlook for market expansion.

Expansion of Public Healthcare Coverage and Access to Generics

Mexico's public healthcare system, particularly IMSS and INSABI, has played a pivotal role in enhancing access to PAH medications by expanding formulary coverage and procuring affordable generics. Government initiatives to increase drug accessibility have been crucial, especially for low-income populations. Public funding for rare disease medications, including PAH therapies, is projected to grow, supported by federal programs aimed at improving chronic disease care. In addition to this, the availability of generic versions of sildenafil, ambrisentan, and tadalafil has also lowered treatment costs, with generic sildenafil priced lower than its branded counterpart, improving affordability and long-term adherence. Partnerships with local manufacturers have ensured steady drug supply, even in rural areas, while public health campaigns have boosted early diagnosis, ensuring timely intervention for more patients.

MEXICO PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET SEGMENTATION:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region/country level for 2026-2034. Our report has categorized the market based on drug class, route of administration, and end user.

Drug Class Insights:

Endothelin Receptor Antagonists (ERAs)

Vasodilators

Phosphodiesterase-5 (PDE-5) Inhibitors

Soluble Guanylate Cyclase (SGC) Stimulators

Calcium Channel Blockers (CCBs)

Prostacyclin and Prostacyclin Analogs

Others

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes endothelin receptor antagonists (ERAs), vasodilators, phosphodiesterase-5 (PDE-5) inhibitors, soluble guanylate cyclase (SGC) stimulators, calcium channel blockers (CCBs), prostacyclin and prostacyclin analogs, and others.

Route of Administration Insights:

Inhalation

Injectable

Oral Administration

A detailed breakup and analysis of the market based on the route of administration have also been provided in the report. This includes inhalation, injectable, and oral administration.

End User Insights:

Hospitals

Clinics

Others

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, clinics, and others.

Regional Insights:

Northern Mexico

Central Mexico

Southern Mexico

Others

The report has also provided a comprehensive analysis of all the major regional markets, which include Northern Mexico, Central Mexico, Southern Mexico, and others.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT

How has the Mexico pulmonary arterial hypertension drugs market performed so far and how will it perform in the coming years?

What is the breakup of the Mexico pulmonary arterial hypertension drugs market on the basis of drug class?

What is the breakup of the Mexico pulmonary arterial hypertension drugs market on the basis of route of administration?

What is the breakup of the Mexico pulmonary arterial hypertension drugs market on the basis of end user?

What is the breakup of the Mexico pulmonary arterial hypertension drugs market on the basis of region?

What are the various stages in the value chain of the Mexico pulmonary arterial hypertension drugs market?

What are the key driving factors and challenges in the Mexico pulmonary arterial hypertension drugs?

What is the structure of the Mexico pulmonary arterial hypertension drugs market and who are the key players?

What is the degree of competition in the Mexico pulmonary arterial hypertension drugs market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MEXICO PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET - INTRODUCTION

- 4.1 Overview
- 4.2 Market Dynamics
- 4.3 Industry Trends
- 4.4 Competitive Intelligence

5 MEXICO PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET LANDSCAPE

- 5.1 Historical and Current Market Trends (2020-2025)
- 5.2 Market Forecast (2026-2034)

6 MEXICO PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET - BREAKUP BY DRUG CLASS

- 6.1 Endothelin Receptor Antagonists (ERAs)
 - 6.1.1 Overview
 - 6.1.2 Historical and Current Market Trends (2020-2025)
 - 6.1.3 Market Forecast (2026-2034)

6.2 Vasodilators

6.2.1 Overview

6.2.2 Historical and Current Market Trends (2020-2025)

6.2.3 Market Forecast (2026-2034)

6.3 Phosphodiesterase-5 (PDE-5) Inhibitors

6.3.1 Overview

6.3.2 Historical and Current Market Trends (2020-2025)

6.3.3 Market Forecast (2026-2034)

6.4 Soluble Guanylate Cyclase (SGC) Stimulators

6.4.1 Overview

6.4.2 Historical and Current Market Trends (2020-2025)

6.4.3 Market Forecast (2026-2034)

6.5 Calcium Channel Blockers (CCBs)

6.5.1 Overview

6.5.2 Historical and Current Market Trends (2020-2025)

6.5.3 Market Forecast (2026-2034)

6.6 Prostacyclin and Prostacyclin Analogs

6.6.1 Overview

6.6.2 Historical and Current Market Trends (2020-2025)

6.6.3 Market Forecast (2026-2034)

6.7 Others

6.7.1 Historical and Current Market Trends (2020-2025)

6.7.2 Market Forecast (2026-2034)

7 MEXICO PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET - BREAKUP BY ROUTE OF ADMINISTRATION

7.1 Inhalation

7.1.1 Overview

7.1.2 Historical and Current Market Trends (2020-2025)

7.1.3 Market Forecast (2026-2034)

7.2 Injectable

7.2.1 Overview

7.2.2 Historical and Current Market Trends (2020-2025)

7.2.3 Market Forecast (2026-2034)

7.3 Oral Administration

7.3.1 Overview

7.3.2 Historical and Current Market Trends (2020-2025)

7.3.3 Market Forecast (2026-2034)

8 MEXICO PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET - BREAKUP BY END USER

8.1 Hospitals

8.1.1 Overview

8.1.2 Historical and Current Market Trends (2020-2025)

8.1.3 Market Forecast (2026-2034)

8.2 Clinics

8.2.1 Overview

8.2.2 Historical and Current Market Trends (2020-2025)

8.2.3 Market Forecast (2026-2034)

8.3 Others

8.3.1 Historical and Current Market Trends (2020-2025)

8.3.2 Market Forecast (2026-2034)

9 MEXICO PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET – BREAKUP BY REGION

9.1 Northern Mexico

9.1.1 Overview

9.1.2 Historical and Current Market Trends (2020-2025)

9.1.3 Market Breakup by Drug Class

9.1.4 Market Breakup by Route of Administration

9.1.5 Market Breakup by End User

9.1.6 Key Players

9.1.7 Market Forecast (2026-2034)

9.2 Central Mexico

9.2.1 Overview

9.2.2 Historical and Current Market Trends (2020-2025)

9.2.3 Market Breakup by Drug Class

9.2.4 Market Breakup by Route of Administration

9.2.5 Market Breakup by End User

9.2.6 Key Players

9.2.7 Market Forecast (2026-2034)

9.3 Southern Mexico

9.3.1 Overview

9.3.2 Historical and Current Market Trends (2020-2025)

9.3.3 Market Breakup by Drug Class

- 9.3.4 Market Breakup by Route of Administration
- 9.3.5 Market Breakup by End User
- 9.3.6 Key Players
- 9.3.7 Market Forecast (2026-2034)
- 9.4 Others
 - 9.4.1 Historical and Current Market Trends (2020-2025)
 - 9.4.2 Market Forecast (2026-2034)

10 MEXICO PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET – COMPETITIVE LANDSCAPE

- 10.1 Overview
- 10.2 Market Structure
- 10.3 Market Player Positioning
- 10.4 Top Winning Strategies
- 10.5 Competitive Dashboard
- 10.6 Company Evaluation Quadrant

11 PROFILES OF KEY PLAYERS

- 11.1 Company A
 - 11.1.1 Business Overview
 - 11.1.2 Products Offered
 - 11.1.3 Business Strategies
 - 11.1.4 SWOT Analysis
 - 11.1.5 Major News and Events
- 11.2 Company B
 - 11.2.1 Business Overview
 - 11.2.2 Products Offered
 - 11.2.3 Business Strategies
 - 11.2.4 SWOT Analysis
 - 11.2.5 Major News and Events
- 11.3 Company C
 - 11.3.1 Business Overview
 - 11.3.2 Products Offered
 - 11.3.3 Business Strategies
 - 11.3.4 SWOT Analysis
 - 11.3.5 Major News and Events
- 11.4 Company D

- 11.4.1 Business Overview
- 11.4.2 Products Offered
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
- 11.5 Company E
 - 11.5.1 Business Overview
 - 11.5.2 Products Offered
 - 11.5.3 Business Strategies
 - 11.5.4 SWOT Analysis
 - 11.5.5 Major News and Events

12 MEXICO PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET - INDUSTRY ANALYSIS

- 12.1 Drivers, Restraints, and Opportunities
 - 12.1.1 Overview
 - 12.1.2 Drivers
 - 12.1.3 Restraints
 - 12.1.4 Opportunities
- 12.2 Porters Five Forces Analysis
 - 12.2.1 Overview
 - 12.2.2 Bargaining Power of Buyers
 - 12.2.3 Bargaining Power of Suppliers
 - 12.2.4 Degree of Competition
 - 12.2.5 Threat of New Entrants
 - 12.2.6 Threat of Substitutes
- 12.3 Value Chain Analysis

13 APPENDIX

I would like to order

Product name: Mexico Pulmonary Arterial Hypertension Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, End User, and Region, 2026-2034

Product link: <https://marketpublishers.com/r/M2BE9FAAE269EN.html>

Price: US\$ 3,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M2BE9FAAE269EN.html>